Category: Hormonal & Midlife Transition

What Clinical Studies Say About Bremelanotide and Low Sexual Desire in Women

Posted on July 29, 2026

Introduction

The central question in the bremelanotide clinical studies is not whether a peptide can be marketed as a libido shortcut. The better question is narrower, and much more useful: in controlled trials, did researchers observe measurable changes in sexual desire and related distress in the women they actually enrolled?

That wording matters. The best-known bremelanotide data come from studies in premenopausal women diagnosed with acquired, generalized hypoactive sexual desire disorder, or HSDD. These were not menopause trials. They were not postpartum trials. They were not broad “female wellness” studies.

For readers sorting through midlife hormone shifts, perimenopause, menopause, relationship stress, sleep disruption, and metabolic change, that creates an awkward but important tension. There is real human trial evidence here. But the people many readers most want to understand — perimenopausal and postmenopausal women — were largely not the trial population.

What bremelanotide clinical studies set out to answer

The clinical research program asked whether bremelanotide, a melanocortin receptor agonist also known as PT-141, could change validated measures of desire and distress in women with acquired, generalized HSDD.

The key word is “measures.” These trials did not simply ask, “Did participants like it?” They used structured instruments, mainly:

• FSFI desire domain: a subscale of the Female Sexual Function Index focused on sexual desire.
• FSDS-DAO item 13: a distress item from the Female Sexual Distress Scale-Desire/Arousal/Orgasm questionnaire, focused on being bothered by low desire.
• Satisfying sexual events: a diary-based count, used in earlier and supportive analyses.

That distinction is not academic nitpicking. A trial can show a statistically greater change on a desire scale and still fail to show a meaningful change in the number of satisfying sexual events. In fact, that split is one of the most important things to understand in this literature.

For basic terminology, Nu-Forme Labs readers can refer to the peptide glossary rather than rehashing receptor biology here.

What the studies did

Early laboratory study in premenopausal women

A small double-blind, placebo-controlled crossover study by Diamond and colleagues enrolled 18 premenopausal women with female sexual arousal disorder. Participants received intranasal bremelanotide, reported in the paper as PT-141, or placebo during separate laboratory sessions.

This was not a real-world HSDD treatment trial. It was a controlled psychophysiology study. Researchers measured genital arousal using vaginal pulse amplitude and also collected subjective sexual response during erotic stimulus exposure.

The sample was tiny. The setting was artificial. But it helped establish the basic research question: could a melanocortin agonist alter sexual response measures in women under controlled conditions?

Dose-finding study in premenopausal women with sexual dysfunction

A later randomized, placebo-controlled phase 2 study led by Clayton and colleagues enrolled 327 premenopausal women. Participants were assigned to subcutaneous bremelanotide doses of 0.75 mg, 1.25 mg, or 1.75 mg, or placebo, used as needed over a 12-week treatment period.

The study assessed sexual function and distress using validated questionnaires and event-based measures. This trial mattered because it moved the research away from a one-session laboratory design and into repeated outpatient use.

It also helped identify the 1.75 mg subcutaneous dose that later became central to the phase 3 program.

Two phase 3 RECONNECT trials

The strongest evidence comes from two randomized, double-blind, placebo-controlled phase 3 trials, commonly referred to as the RECONNECT studies. Together, they randomized 1,247 premenopausal women with acquired, generalized HSDD.

Participants used either bremelanotide 1.75 mg by subcutaneous autoinjector or placebo as needed for 24 weeks. The trials were designed around co-primary endpoints: change in FSFI desire score and change in distress related to low desire, measured by FSDS-DAO item 13.

The comparator was placebo, not another active therapy. The duration was six months. The population was entirely female and specifically premenopausal.

This is the evidence base behind the FDA-approved prescription product Vyleesi. That regulatory fact should not be blurred with research-use PT-141 materials. An approved prescription drug, a compounded preparation, and a research-use peptide are different categories.

What the bremelanotide clinical studies found

In the early crossover study, researchers reported changes in subjective sexual response after intranasal PT-141 compared with placebo in a small group of premenopausal women. Because n was only 18 and the study used a laboratory arousal paradigm, it is best read as a signal-generating study, not proof of real-world outcomes.

In the 327-participant phase 2 randomized trial, subcutaneous bremelanotide was studied across several doses for 12 weeks. The higher-dose groups showed greater changes on sexual function and distress measures than placebo, while adverse events — especially nausea and flushing — were more common with bremelanotide. This study helped shape dose selection, but it was not the final evidence base.

In the two phase 3 RECONNECT trials, the FDA label reports that bremelanotide produced greater mean improvements than placebo on the FSFI desire domain. Across the two studies, mean desire-score changes were approximately 0.5 to 0.6 points with bremelanotide versus about 0.2 points with placebo.

Distress related to low desire also changed more with bremelanotide. FDA summary tables report mean changes of roughly -1.0 to -1.1 on the distress item with bremelanotide versus about -0.7 with placebo.

That sounds encouraging, but the next line is the one careful readers should not skip: the phase 3 trials did not show a significant increase over placebo in the number of satisfying sexual events. Desire and distress scores moved. Event counts did not separate in the same way.

Adverse events were also not subtle. In the FDA label, nausea was reported in about 40% of bremelanotide-treated participants, compared with about 1% of placebo-treated participants. Flushing, headache, vomiting, injection-site reactions, and transient blood-pressure increases were also reported. Discontinuation due to adverse reactions was higher in the bremelanotide arms than in placebo.

So the most honest summary is this: in premenopausal women with acquired, generalized HSDD, randomized trials observed greater changes in validated desire and distress scores with bremelanotide than placebo, but not a clear improvement in satisfying sexual event counts, and tolerability was a major part of the findings.

What this tells us about women specifically

This is one of the rare peptide-adjacent research areas where the main trials were designed specifically around women. The phase 2 and phase 3 studies enrolled 100% female participants, and the pivotal trials focused on premenopausal women with acquired, generalized HSDD.

That is useful. It means the primary evidence is not being back-filled from male data or animal models. The endpoints were also relevant to women’s reported experience: desire and distress, not only physiological arousal.

But the women’s lens also exposes the biggest limitation. These were premenopausal trial populations. Menopausal status was reported in the sense that participants were premenopausal, but the studies were not built to answer questions about perimenopause, menopause, surgical menopause, postpartum recovery, lactation, or midlife endocrine transition.

Results were not meaningfully broken out for perimenopausal versus early reproductive-age participants, because that was not the population structure. For a 48-year-old reader dealing with sleep fragmentation, hot flashes, changing cycle patterns, or hormone therapy decisions, the phase 3 data do not map cleanly onto her situation.

The trial didn’t answer that question. And honestly, that is the answer.

What this doesn't tell us

The bremelanotide clinical studies do not establish broad effects on libido in all women. They studied a specific diagnosis, in a specific population, using specific endpoints.

They also do not tell us much about menopause. Postmenopausal women were not the pivotal population. Perimenopause was not analyzed as its own physiological state. Postpartum and breastfeeding contexts should not be inferred from these trials.

The trials also leave a measurement question. If desire and distress scores improve but satisfying sexual event counts do not clearly separate from placebo, what should be considered the more meaningful endpoint? A person navigating this literature might reasonably pause there. The answer depends on what the trial intended to measure — and on what outcome actually matters to the participant.

Funding and conflicts are another part of the read. The phase 2 and phase 3 programs were industry-funded, with several authors reporting relationships with the sponsor or related companies. That does not invalidate the data. It does mean independent replication and careful endpoint interpretation matter.

Finally, the regulatory distinction is non-negotiable. FDA approval applies to the prescription drug product Vyleesi for a defined indication in premenopausal women. It does not turn all PT-141 or bremelanotide research materials into approved drugs, and it does not answer questions about compounded or research-use supply.

Sources

1. Kingsberg SA, Clayton AH, Portman D, Williams LA, Krop J, Jordan R, Lucas J, Simon JA. Bremelanotide for the Treatment of Hypoactive Sexual Desire Disorder: Two Randomized Phase 3 Trials. Obstetrics & Gynecology. 2019. Study type: human RCT; n=1,247.

2. Clayton AH, Althof SE, Kingsberg SA, et al. Bremelanotide for Female Sexual Dysfunction in Premenopausal Women: A Randomized, Placebo-Controlled Dose-Finding Trial. Obstetrics & Gynecology. 2016. Study type: human RCT; n=327.

3. Diamond LE, Earle DC, Heiman JR, Rosen RC, Perelman MA, Harning R. An Effect on the Subjective Sexual Response in Premenopausal Women with Sexual Arousal Disorder by Bremelanotide, a Melanocortin Receptor Agonist. The Journal of Sexual Medicine. 2006. Study type: human crossover RCT; n=18.

4. ClinicalTrials.gov. Study to Evaluate Bremelanotide in Premenopausal Women With Hypoactive Sexual Desire Disorder, NCT02333071. Study type: human RCT registry record; randomized phase 3 trial.

5. ClinicalTrials.gov. Study to Evaluate Bremelanotide in Premenopausal Women With Hypoactive Sexual Desire Disorder, NCT02338960. Study type: human RCT registry record; randomized phase 3 trial.

6. U.S. Food and Drug Administration. Vyleesi prescribing information. Regulatory source for approved indication, dosing form, safety warnings, and pivotal-trial summary tables.

Working With Nu-Forme Labs

Nu-Forme Labs supplies research-use materials for laboratory investigation, with an emphasis on purity documentation, third-party testing, transparent certificates of analysis, and Canadian supply.

Readers comparing research materials can also review the Nu-Forme Labs PT-141 page, the peptide glossary, the Peptides category, and the guide to reading a Certificate of Analysis. None of that changes the evidence above; it simply helps researchers evaluate materials with cleaner documentation.

Final Thoughts

Bremelanotide is not a vague internet peptide story. There are randomized human trials, including two large phase 3 studies in premenopausal women with acquired, generalized HSDD.

But the strongest data are also narrower than many people assume. Researchers observed changes in desire and distress scores, not a clear increase in satisfying sexual event counts. Adverse events, particularly nausea, were common enough to shape the interpretation.

For women in midlife, the missing evidence is just as important as the available evidence. Perimenopause and menopause deserve their own trials, with endpoints that reflect sleep, vasomotor symptoms, hormone context, relationship factors, and sexual distress as they actually show up in midlife. Until then, the honest read is specific: promising enough to study seriously, too narrow to generalize casually.